ChiCTR2000039318
正在进行
/
/
/
2020-10-23
/
/
adults aged from 18-65 with acute non-specific low back pain
Comparison of diclofenac with tramadol, tizanidine or placebo in the treatment of acute low back pain: multi-centre randomised controlled trial
Comparison of diclofenac with tramadol, tizanidine or placebo in the treatment of acute low back pain: multi-centre randomised controlled trial
To compare the efficacy of the combination of NSAID with tramadol, tizanidine or placebo in improving functional outcome using the primary outcome measure namely RMDQ scores at one week. To investigate the efficacy of these drugs and documenting the changes in the functional outcome, pain intensity score and total loss of work period up to four weeks. To document the side effect profile and the compliance of these drugs in the Hong Kong Chinese population, and understand the further need for pain medications for up to four weeks.
随机平行对照
Ⅳ期
A stratified randomisation technique will be used to ensure that subject s from all three EDs are allocated to equal proportions for the three treatment arms. Sequence generation using random numbers generated from SPSS will be used, with a block size of 12 with four in each arm.
The research nurse/assistant, treating physicians, subjects and outcome assessor will be blinded to the allocation.
Health and Medical Research Fund
/
123
/
2020-10-21
2023-10-20
/
Patients aged from 18 to 65 attending the participating EDs from 9am to 4pm on weekdays for non-specific low back pain, as defined by pain between the twelfth rib and the crease of the buttocks. Patients with sciatica and radicular pain will be included, except those of traumatic in-origin (direct trauma to the back) or those with identified red flag signs for significant pathologies. These patients normally are managed by clinicians within the emergency department, and the emergency medicine ward (EMW) if symptoms are severe. We will recruit patients with a score greater than five on the RMDQ, as previous studies have suggested that the minimal clinically important difference to be five. By recruiting this group of patients, we exclude those expected to resolve no matter if or which analgesics are given.；
登录查看Patients will be excluded if they are non-Chinese in ethnicity, if they present with LBP of more than four weeks in origin or LBP caused by direct trauma. Patients suspected to have conditions other than non-specific acute LBP, including those with red flag signs and symptoms, and those to be admitted to wards other than EMW or those who require operative treatment. Patients who have a RMDQ less than five at baseline, or those who have been given analgesic drugs outside of the protocol in the same ED visit. Pregnant patients, those taking oral contraceptive pills or those who are contraindicated to one or more of the drugs including active gastrointestinal symptoms, renal insufficiency with serum creatinine >150 umol/L, bleeding disorder, on warfarin or other anticoagulants (patients on antiplatelet drugs is not an exclusion criteria, unless deemed unfit by treating clinician), those with known allergy or with significant drug interaction. Those who are not able for follow up, including those without a telephone contact, or with significant co-morbidity which could interfere with assessments, including confusion or dementia will also be excluded. Patients holding a US or Canadian passport will also be excluded following the policy of the clinical trial insurance. Patients will be advised not to receive oral herbal treatment simultaneously, as there maybe potential interaction of the ingredients. If patients wish to continue oral herbal treatment during the trial period, then they will be excluded from the study.；
登录查看中國香港特別行政區食物及衞生局
/
昌郁医药2024-11-22
上海和誉生物医药科技有限公司2024-11-22
云顶新耀2024-11-22
金斯瑞生物2024-11-22
细胞与基因治疗领域2024-11-22
肝脏时间2024-11-22
医药笔记2024-11-22
生物安全情报网2024-11-22
医药速览2024-11-22
亚盛医药2024-11-22
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
